Romidepsin has bioavailability and tissue action in the spinal cord. To
assess the bioavailability of romidepsin through our study, we measured
the expression of biomarkers for drug-tissue response in the spleen and
spinal cord at Day 6 (<24 h after treatment) and Day 10 (after drug
withdrawal). At Day 6, we observed an increase in histone acetylation in
the (a, d) spleen and (b, e) neurons in the spinal cord dorsal horn
(co-localized immunoreactivity of acetyl-histone H3 with NeuN), as
compared with DMSO treatment (*p < 0.05). At Day 10, there was no
difference in histone acetylation between burn-injured treatment groups
(p > 0.05). Additionally, on Day 6, we observed (c, f) a decrease in
Pak1 effector, p-RAF, expression in neurons in the spinal cord dorsal
horn (*p < 0.05). There was no difference in p-RAF expression on Day
10 following drug withdrawal (p > 0.05). In comparisons with Sham, we
observed no difference in biomarker expression levels in burn-injured
animals at any time point (p > 0.05). Scale bars in (a) to (c) are
500 µm. Graphs are mean ± SEM. DMSO: dimethyl sulfoxide.